Regencell Bioscience Holdings Ltd (RGC) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN KYG7487R1002
Regencell Bioscience Holdings Ltd financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Gross profit | -392,743.00 USD | – |
| Operating income | -3.77 m USD | -11.72 m USD |
| EBIT | -3.58 m USD | – |
| Net income | -3.58 m USD | -11.70 m USD |
| Diluted EPS – continuing operations | -0.01 USD | – |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
More stocks
- Zhejiang Longsheng Group Co Ltd (600352.SS)
- Cencosud (CENCOSUD.SN)
- Blackstone Secured Lending Fund (BXSL)
- Graham Holdings Co (GHC)
- Zhongce Rubber Group Co Ltd (603049.SS)
- Rainbow Robotics Inc. (277810.KQ)
- 37 Interactive Entertainment Network Technology Group Co Ltd (002555.SZ)
- Sumitomo Pharma Co Ltd (4506.T)
- Sumco Corp (3436.T)
- Yunnan Wenshan Electric Power Co Ltd (600995.SS)
- Galenica AG (GALE.SW)
- HAEMONETICS CORP (HAE)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.